These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 19965632

  • 1. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia.
    Stam RW, Den Boer ML, Schneider P, de Boer J, Hagelstein J, Valsecchi MG, de Lorenzo P, Sallan SE, Brady HJ, Armstrong SA, Pieters R.
    Blood; 2010 Feb 04; 115(5):1018-25. PubMed ID: 19965632
    [Abstract] [Full Text] [Related]

  • 2. Elevated S100A8/S100A9 expression causes glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia.
    Spijkers-Hagelstein JA, Schneider P, Hulleman E, de Boer J, Williams O, Pieters R, Stam RW.
    Leukemia; 2012 Jun 04; 26(6):1255-65. PubMed ID: 22282267
    [Abstract] [Full Text] [Related]

  • 3. Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia.
    Spijkers-Hagelstein JA, Mimoso Pinhanços S, Schneider P, Pieters R, Stam RW.
    Leukemia; 2013 Apr 04; 27(5):1063-71. PubMed ID: 23334362
    [Abstract] [Full Text] [Related]

  • 4. Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in MLL-rearranged infant ALL.
    Spijkers-Hagelstein JA, Pinhanços SS, Schneider P, Pieters R, Stam RW.
    Leukemia; 2014 Apr 04; 28(4):761-9. PubMed ID: 23958920
    [Abstract] [Full Text] [Related]

  • 5. Glucocorticoid sensitisation in Mixed Lineage Leukaemia-rearranged acute lymphoblastic leukaemia by the pan-BCL-2 family inhibitors gossypol and AT-101.
    Spijkers-Hagelstein JA, Schneider P, Pinhanços SM, Garrido Castro P, Pieters R, Stam RW.
    Eur J Cancer; 2014 Jun 04; 50(9):1665-74. PubMed ID: 24703900
    [Abstract] [Full Text] [Related]

  • 6. Influence of wild-type MLL on glucocorticoid sensitivity and response to DNA-damage in pediatric acute lymphoblastic leukemia.
    Beesley AH, Rampellini JL, Palmer ML, Heng JY, Samuels AL, Firth MJ, Ford J, Kees UR.
    Mol Cancer; 2010 Oct 28; 9():284. PubMed ID: 20979663
    [Abstract] [Full Text] [Related]

  • 7. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia.
    Stam RW, den Boer ML, Meijerink JP, Ebus ME, Peters GJ, Noordhuis P, Janka-Schaub GE, Armstrong SA, Korsmeyer SJ, Pieters R.
    Blood; 2003 Feb 15; 101(4):1270-6. PubMed ID: 12406912
    [Abstract] [Full Text] [Related]

  • 8. Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants.
    Driessen EM, van Roon EH, Spijkers-Hagelstein JA, Schneider P, de Lorenzo P, Valsecchi MG, Pieters R, Stam RW.
    Haematologica; 2013 Jun 15; 98(6):937-44. PubMed ID: 23403319
    [Abstract] [Full Text] [Related]

  • 9. Network-based expression analysis reveals key genes related to glucocorticoid resistance in infant acute lymphoblastic leukemia.
    Mousavian Z, Nowzari-Dalini A, Stam RW, Rahmatallah Y, Masoudi-Nejad A.
    Cell Oncol (Dordr); 2017 Feb 15; 40(1):33-45. PubMed ID: 27798768
    [Abstract] [Full Text] [Related]

  • 10. Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia.
    Schotte D, Lange-Turenhout EA, Stumpel DJ, Stam RW, Buijs-Gladdines JG, Meijerink JP, Pieters R, Den Boer ML.
    Haematologica; 2010 Oct 15; 95(10):1675-82. PubMed ID: 20494936
    [Abstract] [Full Text] [Related]

  • 11. MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.
    Kerstjens M, Driessen EM, Willekes M, Pinhanços SS, Schneider P, Pieters R, Stam RW.
    Oncotarget; 2017 Feb 28; 8(9):14835-14846. PubMed ID: 27588400
    [Abstract] [Full Text] [Related]

  • 12. Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia.
    Stam RW, den Boer ML, Passier MM, Janka-Schaub GE, Sallan SE, Armstrong SA, Pieters R.
    Leukemia; 2006 Feb 28; 20(2):264-71. PubMed ID: 16357833
    [Abstract] [Full Text] [Related]

  • 13. Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia.
    Urtishak KA, Edwards AY, Wang LS, Hudome A, Robinson BW, Barrett JS, Cao K, Cory L, Moore JS, Bantly AD, Yu QC, Chen IM, Atlas SR, Willman CL, Kundu M, Carroll AJ, Heerema NA, Devidas M, Hilden JM, Dreyer ZE, Hunger SP, Reaman GH, Felix CA.
    Blood; 2013 Apr 04; 121(14):2689-703. PubMed ID: 23393050
    [Abstract] [Full Text] [Related]

  • 14. The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia.
    Stumpel DJ, Schneider P, Pieters R, Stam RW.
    Eur J Cancer; 2015 Sep 04; 51(14):2008-21. PubMed ID: 26188848
    [Abstract] [Full Text] [Related]

  • 15. MLL-Rearranged Acute Lymphoblastic Leukemia.
    El Chaer F, Keng M, Ballen KK.
    Curr Hematol Malig Rep; 2020 Apr 04; 15(2):83-89. PubMed ID: 32350732
    [Abstract] [Full Text] [Related]

  • 16. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options.
    Stumpel DJ, Schneider P, van Roon EH, Boer JM, de Lorenzo P, Valsecchi MG, de Menezes RX, Pieters R, Stam RW.
    Blood; 2009 Dec 24; 114(27):5490-8. PubMed ID: 19855078
    [Abstract] [Full Text] [Related]

  • 17. Suppression of the let-7b microRNA pathway by DNA hypermethylation in infant acute lymphoblastic leukemia with MLL gene rearrangements.
    Nishi M, Eguchi-Ishimae M, Wu Z, Gao W, Iwabuki H, Kawakami S, Tauchi H, Inukai T, Sugita K, Hamasaki Y, Ishii E, Eguchi M.
    Leukemia; 2013 Feb 24; 27(2):389-97. PubMed ID: 22918121
    [Abstract] [Full Text] [Related]

  • 18. Differential network analysis and protein-protein interaction study reveals active protein modules in glucocorticoid resistance for infant acute lymphoblastic leukemia.
    Mousavian Z, Nowzari-Dalini A, Rahmatallah Y, Masoudi-Nejad A.
    Mol Med; 2019 Aug 01; 25(1):36. PubMed ID: 31370801
    [Abstract] [Full Text] [Related]

  • 19. Targeting critical kinases and anti-apoptotic molecules overcomes steroid resistance in MLL-rearranged leukaemia.
    de Groot AP, Saito Y, Kawakami E, Hashimoto M, Aoki Y, Ono R, Ogahara I, Fujiki S, Kaneko A, Sato K, Kajita H, Watanabe T, Takagi M, Tomizawa D, Koh K, Eguchi M, Ishii E, Ohara O, Shultz LD, Mizutani S, Ishikawa F.
    EBioMedicine; 2021 Feb 01; 64():103235. PubMed ID: 33581643
    [Abstract] [Full Text] [Related]

  • 20. In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype.
    Ramakers-van Woerden NL, Beverloo HB, Veerman AJ, Camitta BM, Loonen AH, van Wering ER, Slater RM, Harbott J, den Boer ML, Ludwig WD, Haas OA, Janka-Schaub GE, Pieters R.
    Leukemia; 2004 Mar 01; 18(3):521-9. PubMed ID: 14712291
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.